BMMG Releases Benchmark Analysis: The State of U.S. MedTech Commercialization - 2026 Edition
Successful companies are quantifying financial impact and preparing for multi-stakeholder sales cycles
Reed Point, Montana, March 04, 2026 (GLOBE NEWSWIRE) -- Bichsel Medical Marketing Group (BMMG), a global MedTech commercialization firm, today released its flagship benchmark report analyzing the commercialization outlook for MedTech companies entering 2026. The study draws from 173 MedTech executives spanning early-stage through growth-stage companies.
Invited participants were commercial leaders (CEOs, Chief Revenue Officers, and VPs of Sales/Marketing) who recently showcased their technologies at industry events attended by start-ups, investors, and strategic acquirers.
Key findings include:
- 78% of respondents believe 2026 is a good year to launch a new MedTech product in the U.S. (Yes strongly/with caution).
- 86% are very or moderately concerned about U.S. policy/administration changes impacting their business in 2026.
- 84% expect tariffs/trade restrictions to materially affect their cost structure in 2026.
- Top launch drivers cited include hospital financial pressure, regulatory clarity, and adoption appetite among providers.
- BMMG’s Commercial Confidence Index™ average score is 71.1 (0–100); the top quartile begins at 80.1.
“The commercialization playbook is evolving,” said BMMG founder, Lisa Bichsel. “In 2026, adoption is increasingly driven by trust-building, economic clarity, and implementation predictability—not just innovation novelty.”
About the BMMG MedTech Commercial Confidence Index™
The Index is a composite 0–100 score combining commercialization confidence with operational maturity signals such as go-to-market maturity, value story confidence, sales readiness, clinical education maturity, message update cadence, and real-world evidence practices.
“The confidence gap in this year’s Commercial Confidence Index is telling,” said Lauren Dustman, CEO of BMMG. “Top-quartile organizations aren’t simply more optimistic; they’re more disciplined. They lead with economic clarity, scalable strategy, and structured real-world evidence. In 2026, high-performing MedTech companies aren’t just launching products. They’re engineering adoption.”
About BMMG
Bichsel Medical Marketing Group (BMMG) is a global MedTech commercialization authority helping innovative companies move from funding to liquidity with confidence. More than a traditional marketing firm, BMMG provides commercialization intelligence, ecosystem fluency, and integrated strategy across regulatory, reimbursement, investor communications, and go-to-market execution. With a track record supporting 19 acquisitions and 8 IPOs, BMMG partners with MedTech leaders to engineer adoption, mitigate commercialization risk, and build scalable growth platforms. Learn more: www.bichselgroup.com.
Media + Industry Requests
To request the full report, an executive summary, or an interview briefing with BMMG, contact: info@bichselgroup.com.
Lisa Bichsel Bichsel Medical Marketing Group 2106016647 Lisa.Bichsel@Bichselgroup.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
